Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Rheumatology (Oxford).

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A

doi: 10.1093/rheumatology/kex174.

Further Publications Rheumatology

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Arthritis Res Ther

Neuenschwander R, Hebeisen M, Micheroli R, Bürki K, Exer P, Niedermann K, Nissen MJ, Scherer A, Ciurea A

doi: 10.1186/s13075-020-02337-2

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Rheumatoid Arthritis

Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study

Clin Exp Rheumatol.

Burmester G, Nüsslein H, von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

Arthritis Res Ther

Unizony S, McCulley TJ, Spiera R, Pei J, Sidiropoulos PN, Best JH, Birchwood C, Pavlov A, Stone JH

doi: 10.1186/s13075-020-02377-8

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis

Arthritis Rheumatol.

Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, Toniolo M, Exer P, Gabay C, Finckh A; physicians of the Swiss Clinical Quality Management Cohort

doi: 10.1002/art.39691.

Psoriasis

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

J Eur Acad Dermatol Venereol.

Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barri S, Muñoz C, Llamas M, Valentí F, Josune Mitxelena M, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Manuel Carrascosa J

doi: 10.1111/jdv.16439.

Psoriatic ArthritisRheumatoid Arthritis

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Patient Prefer Adherence.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A

doi: 10.2147/PPA.S128665.

Psoriatic Arthritis

Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries

Arthritis Care Res (Hoboken)

Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML

doi: 10.1002/acr.24560

Related content